These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A better medication for treating breast cancer? Johns Hopkins Med Lett Health After 50; 2002 May; 14(3):3. PubMed ID: 12004835 [No Abstract] [Full Text] [Related]
3. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247 [TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors come of age. Dowsett M Ann Oncol; 1997 Jul; 8(7):631-2. PubMed ID: 9296213 [No Abstract] [Full Text] [Related]
7. [Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer]. Bergmann L Strahlenther Onkol; 2001 May; 177(5):273-4. PubMed ID: 11398617 [No Abstract] [Full Text] [Related]
8. Breast cancer face-off. Brink S US News World Rep; 2002 Jun; 132(19):54. PubMed ID: 12066455 [No Abstract] [Full Text] [Related]
9. The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients. Pritchard KI Clin Cancer Res; 2001 Dec; 7(12 Suppl):4356s-4359s; discussion 4411s-4412s. PubMed ID: 11916225 [TBL] [Abstract][Full Text] [Related]
10. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer. Noberasco C; Bajetta E; Zilembo N; Di Leo A; Cappuzzo F; Bartoli C; Bono A; Bichisao E Oncology; 1995; 52(6):454-7. PubMed ID: 7478430 [TBL] [Abstract][Full Text] [Related]
11. Advanced breast cancer in elderly patients: which drug after tamoxifen? Bajetta E Tumori; 2002; 88(1 Suppl 1):S59-60. PubMed ID: 11989927 [No Abstract] [Full Text] [Related]
12. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients. Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852 [TBL] [Abstract][Full Text] [Related]
13. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)]. Bruntsch U MMW Fortschr Med; 2002 Sep; 144(38):20. PubMed ID: 12395697 [No Abstract] [Full Text] [Related]
14. New treatment option for postmenopausal women with early breast cancer. Expert Rev Anticancer Ther; 2002 Dec; 2(6):617. PubMed ID: 12503198 [No Abstract] [Full Text] [Related]
15. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Murray R; Pitt P Breast Cancer Res Treat; 1995 Sep; 35(3):249-53. PubMed ID: 7579495 [TBL] [Abstract][Full Text] [Related]
16. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer]. Tuxen MK; Nielsen DL; Lindberg H; Kamby C Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922 [TBL] [Abstract][Full Text] [Related]
18. Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors. Brodie AM; Santen RJ Crit Rev Oncol Hematol; 1986; 5(4):361-96. PubMed ID: 3094971 [TBL] [Abstract][Full Text] [Related]
19. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Buzdar A; Howell A Clin Cancer Res; 2001 Sep; 7(9):2620-35. PubMed ID: 11555572 [No Abstract] [Full Text] [Related]
20. [Prospects for using aromatase inhibitors in treating endometrial cancer patients]. Bochkareva NV; Kolomiets LA Vopr Onkol; 2001; 47(5):557-61. PubMed ID: 11785095 [No Abstract] [Full Text] [Related] [Next] [New Search]